Filter By:

Treatment with Deramiocel in DMD: Evidence of Long-Term Stabilization in Performance of Upper Limb Function Compared to Matched External Comparators (MDA 2025)

Craig M. McDonald, M.D., Chet Villa, M.D., Cuixia Tian, M.D., Alexander M. Zygmunt, M.D., Nicholas J. Ollberding, Ph.D., Kevin Berth, Upagna Desai, Zena Askerova Ph.D., Nathaniel J. Hogan, Ph.D., Kati S. Maharry, Ph.D., Mark S. Awadalla, Linda Marbán, Ph.D.

View Article

Multi-modal benefits of deramiocel (CAP-1002) in late-stage patients with DMD: a new treatment approach to target skeletal and cardiac muscle pathogenesis (HOPE 2-OLE trial: 36-month data) (WMS 2024)

Craig M. McDonald, M.D., Chet Villa, M.D., Jonathan H. Soslow, M.D., Cuixia Tian, M.D., Alexander M. Zygmunt, M.D., Nicholas J. Ollberding, Ph.D., Kan N. Hor, M.D., Matthew M. Harmelink, M.D., Arun S. Varadhachary, M.D., Ph.D., Susan Apkon, M.D., Veena Ramanna, Upagna Desai, Nathaniel J. Hogan, Ph.D., Kati S. Maharry, Ph.D., Mark S. Awadalla, Linda Marbán, Ph.D.

View Article

Deramiocel (CAP-1002) Demonstrates Disease Modification in Later-Stage DMD Patients 36-Month Safety and Efficacy Results from the HOPE-2 Open Label Extension (PPMD presentation)

View Article

Long Term Safety and Efficacy of CAP-1002 in late-stage patients with DMD: A New Treatment Approach to Target Skeletal and Cardiac Muscle Pathogenesis (24-Month Data from HOPE-2-OLE Study)

Craig M. McDonald, MD, Suzanne Hendrix, PhD, Michelle Eagle, PhD, Matthew M. Harmelink, MD, Arun S. Varadhachary, MD, PhD, Cuixia Tian, MD, Susan Apkon, MD, Chet Villa, MD, Michael D. Taylor, MD, Kan N. Hor, MD, Mitchell Wassom, MS, Upagna Desai, Mark S. Awadalla, Linda Marbán, PhD

View Article

Potency Assay Development for CAP-1002: An Allogeneic Cell Therapy in Phase 3 Clinical Trial for DMD

Minghao Sun, Kristi Elliott, Yujia Li, Lena Trinh, Firouz Mohsenian, Priya Mistry, Meena Murali, Stephanie Adachi, Esther Chin, Ben Canter, Arjang Salehi, Priyanka Ghorpade

View Article

Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial

Craig M McDonald, Eduardo Marbán, Suzanne Hendrix, Nathaniel Hogan, Rachel Ruckdeschel Smith, Michelle Eagle, Richard S Finkel, Cuixia Tian, Joanne Janas, Matthew M Harmelink, Arun S Varadhachary, Michael D Taylor, Kan N Hor, Oscar H Mayer, Erik K Henricson, Pat Furlong, Deborah D Ascheim, Siegfried Rogy, Paula Williams, Linda Marbán, with the HOPE-2 Study Group

View Article

Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial

Raj R Makkar, Dean J Kereiakes, Frank Aguirre, Glenn Kowalchuk, Tarun Chakravarty, Konstantinos Malliaras, Gary S Francis, Thomas J Povsic, Richard Schatz, Jay H Traverse, Janice M Pogoda, Rachel R Smith, Linda Marbán, Deborah D Ascheim, Mohammad R Ostovaneh, João A C Lima, Anthony DeMaria, Eduardo Marbán, Timothy D Henry

View Article

Allogeneic cardiosphere derived cells (CAP 1002) in critically ill COVID 19 patients: compassionate use case series

Siddharth Singh, Tarun Chakravarty, Peter Chen, Akbarshakh Akhmerov, Jeremy Falk, Oren Friedman, Tanzira Zaman, Joseph E. Ebinger, Mitch Gheorghiu · Linda Marbán, Eduardo Marbán, Raj R. Makkar

View Article

MicroRNA composition delineates cardiosphere-derived cell and mesenchymal stem cell extracellular vesicles

Ann-Sophie Walravens, Sasha Smolgovsky, Liang Li, Lauren Kelly, Travis Antes, Kiel Peck, Tanner Quon, Linda Marbán, Benjamin Berman, Luis R. Borlado, Geoffrey de Couto

View Article

Allogeneic Cardiosphere-derived Cells for the Treatment of Heart Failure with Reduced Ejection Fraction: Results of the Dilated cardiomyopathy iNtervention with Allogeneic Myocardially-regeneratIve Cells (DYNAMIC) trial

Chakravarty T, Henry TD, Kittleson M, Lima J, Siegel RJ, Slipczuk L, Pogoda JM, Smith RR, Malliaras K, Marbán L, Ascheim DD, Marbán E, Makkar RR.

View Article